Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03894891 · ClinicalTrials.gov registry record · Phase 2
Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03894891: Completed Phase 2 study, sponsored by Dana-Farber Cancer Institute.
NCT03894891 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03894891, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This research is being performed to treat patient for head and neck cancer patients who have not received prior chemotherapy.
Primary Outcome
LFS defined as time from study registration to earlier of surgical removal of larynx and/or hypopharynx, or death due to any cause. Participants alive with intact larynx and hypopharynx are censored at date of last disease evaluation. Given limited sample size and zero events, the Kaplan-Meier method was not used for estimate of LFS.
Interventions
- DRUG Docetaxel
- DRUG Cisplatin
- DRUG Nivolumab
- RADIATION Intensity-modulated radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-06-11 |
| Est. Completion | 2022-12-16 |
| Phase | Phase 2 |
What the finished NCT03894891 record still lists
NCT03894891 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT03894891 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03894891 about?
NCT03894891 is a clinical study titled "Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer". This research is being performed to treat patient for head and neck cancer patients who have not received prior chemotherapy.
What is the current status of trial NCT03894891?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2019-06-11. Estimated completion is 2022-12-16.
What interventions are being tested in trial NCT03894891?
The interventions under investigation include: Docetaxel (DRUG), Cisplatin (DRUG), Nivolumab (DRUG), Intensity-modulated radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT03894891?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03894891's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI